As a comparison, TPCI not only inhibits GPX4 pathway, but more importantly, is capable of generating a large amount of lipid ROS through ALOX12 activation, so that it holds great potential to be universally applicable on the treatment of a large variety of cancers. This evidence concerns the gene GPX4 and cancer.